UNSPSC 51422304: Desonide

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J280872D1O, chemically known as 16-alpha-hydroxyprednisole-16,17-acetonide but generally known as desonide, which bears US NIH Compound Identifier 12536. European Medicines Agency schedules Desonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07005MIG.

UNSPSC 51422304 Desonide is a Commodity code that nominally names a topical corticosteroid medication, but the recent state and local opportunities tagged to this code show minimal alignment with the pharmaceutical code itself. The two most recent solicitations—Seminole County's 2023 IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's 2026 RFI on direct-to-manufacturer prescription programs—address broader pharmacy procurement, pharmaceutical supply chains, and community health initiatives rather than desonide specifically. The code appears to be applied inconsistently or as a catchall category for pharmaceutical and health-related procurement, suggesting either tagging drift or a mismatch between the formal UNSPSC classification and the actual commodity being sourced.

Issuing bodies using this code include county health departments (Seminole County) and state health and human services commissions (Texas HHS), indicating activity at both county and state health agency levels. Geographic activity is limited to the records available—Florida and Texas—with no evidence of broader concentration across multiple states or jurisdiction types. The Seminole County IFB (posted June 30, 2026, response due July 26, 2023) represents a straightforward pharmaceutical supply procurement, while the Texas HHS RFI (posted April 3, 2026, response due April 3, 2026) pursues market intelligence on direct-to-manufacturer contracting models before issuing a formal RFP. Neither opportunity shows active pursuit of desonide as a named product line, limiting the code's immediate relevance to firms specializing in that specific therapeutic agent.